Health
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – The Lancet
Taking safety, immunogenicity, and production capacity into account, the 3 μg doseof CoronaVac is the suggested dose for efficacy assessment in future phase 3 trials….
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions
Continue Reading
-
General18 hours agoHelp for disabled youths left at the mercy of carers
-
General20 hours agoIran-Israel conflict: Israel strikes Iran’s oil and gas fields, as Tehran warns of ‘more severe’ response
-
General19 hours agoAnthony Albanese to meet Donald Trump at G7 talks in Canada
-
Noosa News10 hours agoIranian Australians share ‘mixed’ emotions after Israeli missiles kill regime officials